The use of bisphosphonates for pain control in children with cancer is not extensively studied. We retrospectively evaluated 35 children with cancer treated with intravenous bisphosphonates for pain management at a single institution from 1998 through 2015. We analyzed pain scores and opioid and adjuvant medication consumption before bisphosphonate administration, daily for 2 weeks, and at 3 and 4 weeks after administration. We also determined the time interval between diagnosis and first administration of bisphosphonates and duration of life after bisphosphonate administration. Mean pain scores were 2.45 (+2.96) and 0.75 (+1.69) before and 14 days after bisphosphonate administration, respectively (P ¼ .25), and morphine equivalent doses of opioids were 5.52 (+13.35) and 5.27 (+9.77), respectively (P ¼ .07). Opioid consumption was significantly decreased at days 4 to 8, days 11 to 12, and week 3 after first bisphosphonate administration. The median duration of life after first bisphosphonate administration was 80 days, indicating its use late in the course of treatment. Bisphosphonates did not significantly improve pain outcomes at 2 weeks, but opioid consumption was reduced at several time points during the first 3 weeks. The use of bisphosphonates earlier in the course of pediatric oncological disease should be evaluated in prospective investigations.
Introduction
Recent advances in cancer-directed therapy have substantially improved the overall survival rate of childhood cancer. 1 However, the outcomes of children with solid tumors, especially bone metastases, remain poor. 1 In general, strategies for pain management in pediatric oncology are based on escalation of treatment options from nonopioid to opioid medications for nociceptive pain and the use of adjuvant classes of medications for neuropathic pain including gabapentinoids and tricyclic antidepressants. Children with bone cancers frequently experience extreme pain and require increased palliative care, which may entail the administration of high doses of opioids. Because pain control is an important aspect of therapy for these patients, the development of an appropriate pain management plan is crucial.
Bisphosphonates (BPs) are structurally similar to inorganic pyrophosphate, with a carbon atom at the center of the 2 phosphonate groups. 2 The mechanism of action of BPs occurs primarily through binding to hydroxyapatite crystals on bone surfaces, resulting in their internalization within osteoclasts. This binding functionally impairs osteoclasts by inhibiting the biochemical pathways necessary for bone resorption. 2 Nitrogencontaining BPs (eg, zoledronate, pamidronate, and alendronate) are more potent osteoclast inhibitors than are non-nitrogencontaining BPs (eg, etidronate and clodronate), and zoledronate is the most potent of BPs.
2 Nitrogen-containing BPs impair osteoclast function by interfering with the mevalonate pathway, causing cytoskeletal defects, whereas non-nitrogenous BPs disrupt adenosine triphosphate production. Additionally, the secondary effect of all BPs is a decrease in the number of mature osteoclasts through apoptosis. 3 As inhibitors of osteoclasts, BPs limit bone resorption and reduce the pain associated with the breaking down of bone tissue. Intravenously administered BPs reduce the risk of skeletal complications and alleviate pain in adult patients with metastatic cancer. 4, 5 Because BPs protect skeletal integrity and produce acute analgesic effects in bony conditions lacking the etiology of osteolytic or inflammatory responses, BPs are recommended to control chronic pain caused by bone metastases. 6 The side effects of BPs include electrolyte disturbances, flulike symptoms, nausea, and less commonly but more seriously, osteonecrosis of the jaw and renal dysfunction. 7, 8 Electrolyte abnormalities, specifically hypocalcemia and hypophosphatemia, are common. Therefore, inpatient monitoring is recommended for 3 to 4 days postinfusion, and calcium supplementation (with or without vitamin D) should be considered. 7, 9 Although pamidronate and zoledronate are frequently used to reduce skeletal complications and treat bone pain in adults with metastatic bone disease, [10] [11] [12] few studies have reported the use of BPs in children with cancer. 1, 13 In one study, 2 pediatric patients with pain from acute lymphoblastic leukemia (ALL) received pamidronate for vertebral fractures. 13 In another study, a retrospective analysis of a series of case reports revealed that zoledronate was used in 19 pediatric patients with metastatic cancer. 1 Despite the limited use of BPs in children, BP therapy may improve pain control and mobility and prevent fractures in children with low bone mineral density caused by cancer or cancer-directed therapy. 13 In addition, BPs may improve bone strength and pain control in children with metastatic disease in one or more bone sites. 1 Here, we review our institutional experience with the use of intravenous BPs in children with cancer for the indication of pain control. We used a pain outcome methodology that we verified in a previous study of pain outcomes in pediatric oncology. 14 
Methods
This study was approved by the institutional review board. We evaluated the use of intravenous BPs at a single pediatric oncology academic research institution treating children, adolescents, and young adults, from September 1998 to November 2015, for the indication of reducing pain related to cancer. Patients treated for other indications such as hypercalcemia, fracture, or osteopenia/osteoporosis or patients who received oral BPs were excluded from this analysis.
We collected the following data: (i) patient characteristics-including age, sex, race/ethnicity, and disease diagnosis; (ii) drug characteristics-including BP type, dosing information, number of administrations, and the time interval between administrations; (iii) pain outcomes-including pain intensity and pain medication (opioid or adjuvant medications) consumption; and (iv) the duration of disease progression before and after BP administration-including the duration of life after the initiation of BP therapy and the time from diagnosis to BP administration. If a patient received more than 1 dose of BPs, the pain intensity and pain medication data pertaining to only the first BP dose were evaluated. Pain intensity was calculated as the mean value of all available daily pain scores for each patient.
Pain assessment was standardized with age-appropriate tools: the Face, Legs, Activity, Cry, Consolability scale 15 for children younger than 4 years; the Wong-Baker FACES scale 16 for patients aged 4 to 7 years; and the numerical pain scale 17 for patients older than 7 years; all scales are 11-point scales from 0 to 10. Pain medication data included opioids and all adjuvant medications for the treatment of pain. Opioid medications data included oral opioids and intravenous opioids (either as patient-controlled analgesia or intermittent, asneeded doses). For analysis, all opioid doses were converted to intravenous morphine equivalent doses (mg/kg/d) by opioid equianalgesic potency. The following potency ratios were used: fentanyl:morphine, 100:1; hydromorphone:morphine, 5:1; and oral codeine:morphine, 1:12. The adjuvant pain medications in the categories of gabapentinoids and tricyclic antidepressants were noted, and the doses were analyzed.
Pain outcome measures were collected before and after BP administration as follows: within 14 days before BP administration (day À1), the day of BP administration (day 0), daily postadministration for the first 2 weeks (days [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , and at 3 and 4 weeks postadministration (week 3 and week 4). The duration of life after initiating BP therapy was calculated from the first day of BP treatment to the last day of life. The duration of time between the date of diagnosis and the first dose of BP was also calculated.
Descriptive statistics were computed for the patients' characteristics at baseline and after BP administration. The differences in pain score distribution between baseline and follow-up time points were examined using Wilcoxon signed rank test for the paired and ordinal data, and the P values were then adjusted for multiplicity using the false discovery rate method. 18 Kaplan-Meier estimators were calculated for time to death and time to BP administration for patients with neuroblastoma or nonneuroblastoma cancer diagnoses. These times were tested with Wilcoxon rank sum test, as no censoring was observed among all patients. A correlation analysis was also performed to determine the relation between duration of life and time without BP administration.
Results

Patient Characteristics
During the study period, 35 patients received intravenous BP treatment for the indication of pain reduction and had evaluable pain outcome data. The patient characteristics are presented in Table 1 . The most prevalent diagnosis was neuroblastoma with bone metastases (23 patients, 66%). The majority of patients were younger than 13 years (29 patients, 83%), with a median age of 9.2 years (range, 3.1-20.4). All patients in this study died as a result of their oncological diagnoses.
Bisphosphonate Therapy
Thirty-five patients received 58 doses of BPs intravenously, including 55 doses of zoledronic acid and 3 doses of pamidronate, and were included in the analyses. Zoledronate was administered to the majority of patients (33/35, 94.3%), with a mean of 1.68 doses per patient, administered at a mean of 47 days between doses, at a mean dose of 2 mg/m 2 . Two patients received pamidronate and zoledronate in subsequent doses.
Pain Outcomes
For all pain outcome measures (ie, pain scores and opioid or adjuvant medication consumption), data pertaining to the first BP dose were analyzed (Table 2 ). Mean pain scores were 2.45 (+2.96) and 0.75 (+1.69) before and 14 days after BP administration, respectively (P ¼ .25), and morphine equivalent doses of opioids were 5.52 (+13.35) and 5.27 (+9.77), respectively (P¼ .07). Opioid consumption was significantly decreased at days 4 to 8, days 11 to 12, and week 3 after first BP administration (Table 2) . Bisphosphonates did not appear to significantly improve pain outcomes at 2 weeks, but opioid consumption was reduced at several time points during the first 3 weeks.
Six patients received adjuvant gabapentin for pain, which was administered at a median dose of 1350 mg/d (range, 100-3600 mg/d) at day À1 and at 2700 mg/d (range, 900-3600 mg/d) at week 4. Two patients received adjuvant amitriptyline, which was administered at a dose of 25 mg/d at day À1 and at a median dose of 37.5 mg/d (range, 25-50 mg/d) at week 4.
Duration of Disease Before and After Initiation of BP Therapy
We analyzed the relative time points of the first BP dose during the treatment course in relation to their date of diagnosis and date of death, respectively. The median time from the first BP dose to the time of death was 80 days, and the median time from diagnosis to the first BP dose was 805 days. For patients with neuroblastoma (the most prevalent diagnosis in our study), the median time from their first BP dose to death was 80 days and the time from diagnosis to their first BP dose was 936 days. All patients included in this study died of their disease.
Discussion
Currently, BPs have been reported in the treatment of solid tumors with bone involvement, 1,7,19 ALL, 13, 20, 21 and Langerhans cell histiocytosis. 22 However, the number of reports describing the use of BPs for treating children with cancer is limited, especially when pain is the outcome measured.
In the relatively few studies that have investigated BP administration in children, BPs were well tolerated, transiently arrested endochondral ossification, improved bone mineralization, decreased the risk of vertebral fractures, and provided acute pain control. 1, 2, 13, [20] [21] [22] Although the sample sizes in these studies were relatively small and measurements of pain outcomes were not standardized, these findings, nevertheless, suggest that BPs are clinically beneficial as a treatment for pain in pediatric patients with bone cancer.
Here, we investigated pain outcomes with a design focused on pain intensity, opioid consumption as morphine equivalent dose per day, and the use of adjuvant medications for pain. Additionally, we evaluated the timing of BP treatment in relation with the times of diagnosis and death. Neuroblastoma with bone metastases was the most frequent cancer type in our study, and patients younger than 13 years composed the most prevalent age group. The predominance of neuroblastoma with bone metastases in our study, as opposed to primary bone tumors such as osteosarcoma and Ewing sarcoma, may be due to the higher prevalence of neuroblastoma in the general pediatric population. 23 We evaluated intravenous administration of BPs because this route is associated with high potency and advantageous dose-response, including pamidronate and zoledronate. The dosing used in our study ( 4 mg/m 2 ) is consistent with previous reports of the use of BPs in children with no major adverse effects, including renal dysfunction or osteonecrosis of the jaw. 8, 19 The current zoledronate dosing recommendation at our institution is 2.3 mg/m 2 , with a time interval of at least 4 weeks between doses for the indication of bone pain related to metastases.
The lack of statistically significant differences in pain intensity scores after BP administration may have multifactorial implications. We observed a fluctuating pattern of pain intensity and opioid consumption over the 4 weeks after BP administration. In general, pain intensity appeared to be mild to moderate in the group when evaluated as a whole. This may reflect dynamic changes in pain treatment options, including escalation of treatment with multiple medications. Because pain management medication data have not been reported in any previous studies of BP administration in children, we were unable to compare our results with those of other studies. Nevertheless, the opioid consumption observed in our study was generally high, with a maximum of 178 mg/kg/d morphine equivalent dose. This aggressive opioid treatment may have overpowered any observable analgesic effects of BP. However, it is more likely that the BPs appeared to be ineffective because of the limited duration of life of the patients, as BPs were administered late in the course of disease and close to the end of life.
The limited duration of life observed in our study reflects the general indication of the use of BPs as a late option in the armamentarium of pain management. Indeed, BPs are usually only considered after traditional pharmacologic options for pain management (eg, opioids or adjuvant medications, such as gabapentin, amitriptyline, or methadone) have been exhausted. 1, 8, 10 Others have recommended that BPs should be used as an earlier intervention. 20 In a phase I study of zoledronate and low-dose cyclophosphamide in recurrent/refractory neuroblastoma in pediatric patients, the median overall survival was 12.3 months. 19 This is considerably longer than the median overall survival observed in our study.
Among the limitations of this study, one must consider the retrospective design and the inclusion of time points when participants were outpatients, which limited the availability of pain score and opioid consumption data. Additionally, we did not evaluate a number of variables that could have influenced pain outcomes and possibly the course of disease, including the use of radiation therapy, steroids and nonsteroidal anti-inflammatory drugs, specific chemotherapy (eg, palliative chemotherapy for pain control), and psychological support for teaching nonpharmacological interventions for pain.
In summary, the use of BPs for pain indications in children did not appear to affect pain intensity with statistical significance, while the opioid consumption was decreased at several time points after administration of BPs. The consumption of high doses of opioids observed in our study may have masked a more modest analgesic effect of BPs. Our observation that BPs were given late in the course of life is notable. Several reports have demonstrated a tumor suppressive role of BPs, especially zoledronate, in primary and secondary adult bone cancers. [24] [25] [26] We recommend the investigation of the use of BPs earlier in the course of pediatric oncological disease, in prospective investigations.
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